Pharvaris: Funding, Investors & Team (Sep 2026)
Pharvaris is a clinical-stage company working on bringing a new oral bradykinin B2 receptor antagonist to patients as an alternative to injected therapies for hereditary angioedema and other related conditions. Their lead drug candidate, PHA121, is a potent small-molecule bradykinin B2 receptor antagonist currently in Phase 1 clinical study. The co-founders of Pharvaris include the inventor of icatibant and key leaders from Jerini AG, who developed icatibant for HAE treatment, now marketed as Firazyr® by Takeda.
Pharvaris has raised $483M across 4 funding rounds on record, the most recent an undisclosed round of $132M announced in May 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Pharvaris Company Profile and Key Stats
Latest funding round on record: May 2026.
Pharvaris Funding Rounds
Pharvaris raised $80.0M in an undisclosed round announced in Nov 2020.
2.6 years later, an undisclosed round of $70.0M was announced in Jun 2023.
2.1 years later, an undisclosed round of $201M was announced in Jul 2025.
10 months later, an undisclosed round of $132M was announced in May 2026.
Pharvaris Founders and Leadership Team
Contact details for the Pharvaris team: 2 of 2 have an email address on file.
Start 14-day free trial →Pharvaris Funding Compared to Other Biotechnology Startups
Pharvaris' latest round of $132M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Pharvaris in Biotechnology and Zug
Companies Similar to Pharvaris
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
Pharvaris Funding FAQs
What does Pharvaris do?
Pharvaris is a clinical-stage company working on bringing a new oral bradykinin B2 receptor antagonist to patients as an alternative to injected therapies for hereditary angioedema and other related conditions. Their lead drug candidate, PHA121, is a potent small-molecule bradykinin B2 receptor antagonist currently in Phase 1 clinical study. The co-founders of Pharvaris include the inventor of icatibant and key leaders from Jerini AG, who developed icatibant for HAE treatment, now marketed as Firazyr® by Takeda.
How much funding has Pharvaris raised?
Pharvaris has raised $483M across 4 rounds on record. The most recent is an undisclosed round of $132M announced in May 2026.
When did Pharvaris last raise funding?
Pharvaris' most recent funding round on record is an undisclosed round of $132M, announced in May 2026.
Who founded Pharvaris?
FundedIQ lists Anne Lesage (Founder) at Pharvaris.
Who is the CEO of Pharvaris?
Berndt Modig is listed as CEO at Pharvaris.
Where is Pharvaris headquartered?
Pharvaris is based in Zug, Switzerland.
How many employees does Pharvaris have?
Pharvaris is in the 101-250 employee band.
How does Pharvaris' funding compare to other Biotechnology startups?
Pharvaris' latest round of $132M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Pharvaris Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Pharvaris is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.